Product: Tulip, sold as a frontline operations platform and, in pharma marketing, as a composable MES made of no-code apps (electronic batch records, weigh and dispense, logbooks, packaging, sampling). Public plans: Essentials, Professional, Enterprise, and Regulated Industries. Vendor: Tulip Interfaces, Inc., a Delaware corporation, 77 Middlesex Ave, Suite A, Somerville, MA 02145. The January 2026 funding release is datelined Boston and names Somerville as headquarters. Category: Frontline operations / composable operations software. Adjacent. Tulip's navigation says "MES for Pharmaceuticals," and its library ships an app suite for batch production steps. The sources show app-based workflows and single-process use cases, not one execution system covering an entire pharmaceutical plant. Verification date: 2026-10-03. Scope: Public sources only.

1. Overview

Tulip is a no-code frontline operations platform whose pharma app suite, marketed as a composable MES, covers weigh and dispense, eBR review by exception, packaging, sampling, and equipment logbooks. It stays adjacent because the suite is a set of customer-configured apps rather than a plant-wide GMP system of record, and its buyers are pharmaceutical and biotech manufacturers that want guided operator workflows, electronic records, and faster change, starting at a published $100 per interface per month with the 21 CFR Part 11 tier quote-only.

Tulip's pharma page, "MES for Pharmaceutical Manufacturing," carries the subtitle "Audit-ready. Easily validated. Built for change." It sells a flexible MES for regulated pharmaceutical operations that streamlines compliance, reduces release delays, and digitizes batch records, and calls the system "composable, not rigid," no-code, cloud-native, and "ready to integrate with QMS, LIMS, and ERP." (Composable MES for pharma.) The older URL https://tulip.co/industries/pharma-manufacturing/composable-mes/ serves the same page.

The plans page aims Essentials at "basic production visibility, quality, and assembly," Professional at sensor and machine data, Enterprise at multi-site governance, and Regulated Industries at food, drug, medical device, and aerospace and defense. (Plans.)

Customers build apps that run on Tulip Player. The pharma library suite is a downloadable starting point: blending, tableting, weigh and dispense, packaging, sampling and in-process control, eBR review with review by exception, equipment logbooks and cleaning, and dashboards. (Library suite.)

Boundaries:

• Not a plant-wide classic MES. The library describes configurable apps on a common data model the customer extends. The pharma FAQ contrasts Tulip with "traditional monolithic systems" and deployments "that take years." Tulip claims interfaces to warehouse, ERP, and automation layers; it does not claim to be the system of record for an entire GMP site.
• Not a QMS or a LIMS. The pharma page integrates with both. Sample management and non-conformance appear only as use-case links.
• Part 11 is not on the $100 plan. Electronic signatures for 21 CFR Part 11, auditable record history, 0-RPO, the validation pack, and long-term support releases sit on the Regulated Industries tier (also offered as an Enterprise add-on), not on Essentials. (Plans page.)
• The MES label is an extension, not a rename. Tulip announced the Composable MES for Pharma at Operations Calling 2024 as an extension of an earlier cMES app suite. The January 2026 release still calls the company a frontline operations platform. (Blog, 18 Oct 2024; Series D.)

2. Company and product identity

Point	Fact	Source
Contracting party	Tulip Interfaces, Inc., Delaware corporation, 77 Middlesex Ave, Suite A, Somerville, MA 02145. Terms last updated 8 May 2025.	Terms of Service
Orders	The terms, referenced documents, order forms, and SOWs form the entire agreement, with a modification process. Order forms are not public.	Terms
Federal end use	Section 16.11: elements of the products are commercial computer software developed fully at private expense; federal end use follows the terms.	Terms
CEO	Natan Linder.	Series D release, 13 Jan 2026
Series D	Page title: "Tulip Secures $120M Series D." Body, Boston, 13 January 2026: Mitsubishi Electric invested and signed a strategic alliance. The dek puts the valuation at $1.3 billion. The $120 million figure appears in the title, not in the body sentences around the dateline.	Series D page
Operating counts	"In 2025 43K Tulip apps enabled the work of 60K frontline workers across 1K customer sites in 45 countries." Headcount "+300" after 135% growth over three years. Offices: Somerville, Munich, Budapest, Singapore, Tel Aviv, Tokyo.	Same release (company statistics)
Analyst placements	Tulip reports "Leader in the IDC MarketScape for Discrete MES" and "Leader in ABI Research's MES for Process Industries Competitive Assessment," among "nearly 20" reports.	Same release
Navigation labels	Frontline platform; "MES for Discrete," "MES for Pharmaceuticals," "MES for Medical Device," "Laboratory Operations."	Plans page, 2026

3. Pharma and biotech relevance

• Oral solid dose-style app suite. Blending, tableting, weigh and dispense, packaging, sampling and IPC, and eBR review. E-signatures and validation checks support eBR data integrity, and eBR review runs by exception. A template library, not a customer batch record. (Library.)
• 21 CFR Part 11 and Annex 11 claims. The pharma FAQ says the platform "supports GxP-regulated environments" with audit trails, electronic signatures, access control, and secure data handling "to meet 21 CFR Part 11 and Annex 11 compliance requirements out of the box." The plans page puts Part 11 e-signatures on the Regulated Industries tier. Vendor claims; no FDA clearance. (Pharma solution page; plans page.)
• Validation offer. Regulated Industries includes "Validation Pack (Access to Test Reports and traceability matrix)" and long-term support releases. (Plans page.)
• Sharp Packaging. With implementation partner Sequence, Sharp ran Tulip on Amazon Web Services for secondary packaging of investigational medicinal products and reports a 30% faster process than manual, with guided work instructions and electronic quality reports. The pharma page's unnamed "30% faster clinical trial packaging" tile uses the same figure. (Sharp.)
• Unnamed "large multinational biopharmaceutical company." Line changeover fell from 14 days to 3 days with line-clearance and SOP apps; the pharma page's anonymous tile tells the same story. (Case.)
• AstraZeneca. The January 2026 release says Tulip "supports global manufacturers like Astrazeneca, Richemont, Stanley Black & Decker, and DMG Mori." A name in a press list, not a GMP deployment record. (Series D release.)

Other pharma-page tiles ("↓29% in changeover time," "↓20 minutes in batch turnaround time," "↓20% in process variability") carry no account, baseline, or year.

4. Capabilities

Capability	Status	Fact	Source
Guided operator apps	Pharma suite	Enforce SOPs with guided workflows; product-step templates.	Library
Electronic batch record content	Pharma suite	Blending, tableting, weigh and dispense, packaging, sampling and IPC, eBR review.	Library
Review by exception	Pharma suite	"Review batch records in real time with review by exception."	Library
Equipment logbooks and cleaning	Pharma suite	Cleaning cycles and a searchable equipment record.	Library
e-signatures and Part 11	Plan feature	Not on Essentials. Enterprise lists a Regulated Industries add-on: "eSignatures (21CFR-P11)." Regulated Industries: "eSignatures for Compliance (21 CFR Part 11)."	Plans
Audit history and 0-RPO	Plan feature	"Auditable record history" and "0-RPO (Recovery Point Objective)" / "Zero Data Loss Protection (0-RPO)" on the regulated tier. No RTO.	Plans
Validation pack and LTS	Plan feature	Test reports, traceability matrix, long-term support releases, customer audit privileges.	Plans
AI agent	Library	"AI Agent: Shift Handoff Summary" next to the eBR apps. No model or validation method stated.	Library
Line clearance	Tulip case study	Unnamed biopharma; 14 days to 3 days.	Case study
Clinical secondary packaging	Tulip case study	Sharp; guided instructions; 30% faster.	Sharp case
GMP weigh and dispense with potency math	Absent	The app "assists accurate weighing and dispensing." No potency adjustment, scale calibration status, or barcode rules.	Library
Native scheduling, warehouse control, ERP	Absent	ERP is an integration target.	Pharma FAQ

5. Architecture and deployment

• Cloud. Sharp's deployment ran on Amazon Web Services. A support article (updated 18 September 2022) offers AWS GovCloud as an option between general cloud and on-premise: Tulip manages and scales resources, AWS's GovCloud certifications are quoted from AWS, and Tulip remains responsible for information inside the platform. Contact: sales@tulip.co. (GovCloud doc.)
• Hosting add-ons, unpriced. "AWS GovCloud"; "FedRAMP Environment," described as "an environment that has achieved FedRAMP Moderate Equivalency" (Tulip's wording, not a FedRAMP marketplace listing); "Cloud Choice" of AWS or Microsoft Azure.
• Professional connectivity. HTTP and SQL connectors, on-premise connector host, Tulip API, SSO/SAML/LDAP, GPIO and edge devices. Essentials has USB device integrations only. (Plans page.)
• The interface is the unit. An interface is a device running apps through Tulip Player: computer, tablet, phone, wearable, browser, or dashboard screen. Plans are priced on monthly active interfaces. (Plans FAQ.)

Not published: database product, tenant-isolation white paper, backup RPO for Essentials, numeric RTO.

6. Integrations

Kind	Fact	Weight
Tulip API	Professional and above.	Plan feature.
HTTP and SQL connectors	Professional: "3rd-Party Integrations: HTTP & SQL Connectors."	Connector types, not a named SAP or Veeva certification.
On-premise connector host	Professional.	Connectivity option, not an on-prem platform. On-prem as a deployment appears in the GovCloud article.
Machine data	"Machine Monitoring" add-on: OPC UA, MQTT, Node-RED, Tulip API, edge devices.	No device matrix.
QMS, LIMS, ERP, historians	Pharma FAQ: "open API and connectors" to those systems and lab equipment.	Category claim, no named products.
Partner implementation	Sequence on the Sharp project.	One partner, one project.
AI Actions	Metered add-on: AI Composer, AI Chat, AI Trigger Actions, translation, Tables Chat.	Usage meter, not an integration catalog.

7. Pricing and commercial model

Tulip publishes list prices for Essentials and Professional. Enterprise and Regulated Industries, the tier with 21 CFR Part 11 e-signatures, are quote-only.

Plan	Public price	Fit
Essentials	$100 per month per interface, billed annually. 10 interface minimum.	Basic production visibility, quality, and assembly. Apps, Tulip AI, Tables, Analytics, USB devices. No Part 11 e-signatures.
Professional	$250 per month per interface, billed annually. 10 interface minimum.	Sensors, machines, adjacent systems. Adds edge connectivity, SSO, HTTP and SQL connectors, on-prem connector host, API.
Enterprise	Quote-only ("Let's Chat" / "Contact us to learn more"). 10 interface minimum.	Multi-site governance, workspaces, app approval workflows. Regulated Industries add-on, including Part 11 e-signatures.
Regulated Industries	Quote-only. 10 interface minimum.	Food, drug, medical device, aerospace and defense. Part 11 e-signatures, auditable history, 0-RPO, validation pack, LTS, audit privileges.

(Plans page, retrieved 2026-10-03.)

• Each priced card still says "Contact Sales." Tulip charges per interface, not per user.
• AI actions and automation tasks come with included allotments. Unused automation tasks do not roll over; more can be bought.
• No price is published for add-ons, GovCloud, FedRAMP equivalency, cloud choice, or professional services.
• Tulip prints no annual contract total. A 10-interface minimum is a floor, not a quote.
• The May 2025 terms incorporate order forms and publish no rate card.

Exact-name searches on 3 Oct 2026 found no award naming Tulip Interfaces on USAspending (contracts from 1 Oct 2007), EU TED, or SAM.gov opportunities. UK Contracts Finder's keyword filter returned only unrelated notices, so no UK result is reported. No AWS Marketplace price is cited.

Questions a buyer should ask

1. Which plan is in the quote? Part 11 e-signatures are not on the $100 plan.
2. How are monthly active interfaces counted, and is 10 still the floor for one packaging line?
3. Are the pharma library apps included or a separate entitlement?
4. Is 0-RPO a contractual recovery objective for the regulated tier, and what is the RTO?
5. Which cloud: commercial AWS, Azure, GovCloud, or the FedRAMP-equivalency environment, and is that environment authorized or "equivalent" in Tulip's wording?
6. What do HTTP and SQL connectors not cover (SAP IDoc, a named QMS, a named LIMS)?
7. Is Sequence or another partner required, and are services priced in the software line?
8. What is in the validation pack, and what must the customer still author?
9. How are AI actions metered in a GxP app, and are they allowed on a validated release?
10. Which release is LTS, and what does a non-LTS cloud update do to a validated app?

8. Implementation and validation support

The pharma page promises "Go live in 90 days with validated digital workflows." The FAQ says "as little as 90 days" for logbooks, weigh and dispense, sampling, packaging, and eBR review. Vendor targets; neither case study gives a project duration.

Professional services come from Tulip and partners. Premium support (24/7 for critical issues) is an add-on. No rates.

The regulated tier includes a validation pack (test reports, traceability matrix) and customer audit privileges. The library links a "Composable Solutions Learning Path" and "Best Practices for GxP App Building." Tulip publishes no completed IQ/OQ set and no GAMP 5 category.

9. Customer evidence

Account	What is public	Limit
Sharp Packaging	Clinical secondary packaging of IMP, with Sequence, on AWS. 30% faster than manual. Quality reports digitized.	Tulip-authored. Clinical packaging, not a commercial drug-product MES.
Unnamed multinational biopharma	Line clearance and SOP apps; changeover 14 days to 3 days.	No name. One process.
AstraZeneca, Richemont, Stanley Black & Decker, DMG Mori	Named in the 13 January 2026 release as manufacturers Tulip "supports."	No scope, product, or go-live year.
"1K customer sites" in 2025	Same release.	"Site" undefined. Not pharma-only.

10. Competitive and third-party context

Tulip reports Leader placements in an IDC MarketScape for discrete MES and an ABI Research assessment of MES for process industries. A discrete-MES placement says nothing about the pharma eBR apps.

The pharma FAQ says Tulip is "recognized by Gartner, Forrester, and customers" and cites G2 leadership rankings, with no report title, date, or score.

11. Changes and renames

• 18 September 2022: GovCloud support article updated.
• 18 October 2024: Composable MES for Pharma announced at Operations Calling 2024.
• 8 May 2025: terms updated (Delaware corporation, Somerville).
• 13 January 2026: Mitsubishi Electric investment; $120 million Series D (title); $1.3 billion valuation.
• 2026 plans page: $100 and $250 per interface per month, billed annually; Enterprise and Regulated Industries quote-only.

Tulip remains the company and platform name. The MES label covers an app suite.

12. Source library

Full URL list and procurement notes: ../sources/tulip-sources.md.

Claim-level records: ../evidence/tulip.evidence.jsonl.

Primary pages:

• https://tulip.co/solutions/composable-mes-for-pharma/
• https://library.tulip.co/suites/composable-mes-for-pharma
• https://tulip.co/plans/
• https://tulip.co/legal/terms-of-service/
• https://tulip.co/press/tulip-secures-120m-series-d/
• https://tulip.co/case-studies/sharp-packaging/
• https://tulip.co/case-studies/pharmaceutical-case-study/
• https://tulip.co/blog/introducing-the-composable-mes-for-pharma/
• https://support.tulip.co/docs/deploy-tulip-in-aws-govcloud